XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants

被引：0

作者：

Levy, Matthew E. ^{[1
]}

Chilunda, Vanessa ^{[1
]}

Heaton, Phillip R. ^{[2
]}

Mckeen, Deran ^{[3
]}

Goldman, Jason D. ^{[4
,5
]}

Davis, Richard E. ^{[6
]}

Schandl, Cynthia A. ^{[7
]}

Glen, William B. ^{[7
]}

Mcewen, Lisa M. ^{[1
]}

Cirulli, Elizabeth T. ^{[1
]}

Wyman, Dana ^{[1
]}

Dei Rossi, Andrew ^{[1
]}

Dai, Hang ^{[1
]}

Isaksson, Magnus ^{[1
]}

Washington, Nicole L. ^{[1
]}

Basler, Tracy ^{[1
]}

Tsan, Kevin ^{[1
]}

Nguyen, Jason ^{[1
]}

Ramirez, Jimmy ^{[1
]}

Sandoval, Efren ^{[1
]}

Lee, William ^{[1
]}

Lu, James ^{[1
]}

Luo, Shishi ^{[1
]}

机构：

[1] Helix, San Mateo, CA 94401 USA

[2] HealthPartners, Dept Pathol & Lab Med, Bloomington, MN USA

[3] HealthPartners Inst, Bloomington, MN USA

[4] Providence Swedish Med Ctr, Swedish Ctr Res & Innovat, Seattle, WA USA

[5] Univ Washington, Div Allergy & Infect Dis, Seattle, WA USA

[6] Childrens Hosp, Providence Sacred Heart Med Ctr, Spokane, WA USA

[7] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC USA

来源：

FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷

关键词：

COVID-19; vaccines; SARS-COV-2; variants; hospitalization; emergency room visits; epidemiology; IMMUNOCOMPETENT ADULTS;

D O I：

10.3389/fimmu.2025.1470609

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

As part of a multi-state viral genomic surveillance program, we conducted a case-only analysis to evaluate the effectiveness of XBB.1.5-adapated mRNA vaccines in preventing severe illness among individuals with medically attended SARS-CoV-2 infection. We compared prior receipt of an XBB.1.5-adapted mRNA vaccine between SARS-CoV-2-infected adults with inpatient or emergency department (ED) visits (as a proxy for severe illness) vs those with outpatient visits (as a proxy for mild illness). Among 6,551 patients between September 2023 and January 2024, 6.1% with inpatient or ED visits vs 12.0% with outpatient visits had received XBB.1.5 vaccination (adjusted odds ratio [aOR]=0.41; 95% confidence interval [CI]: 0.32-0.53). This protective association was weaker among JN.1 (aOR=0.62; 95% CI: 0.40-0.96) vs XBB-lineage (aOR=0.28; 95% CI: 0.18-0.43) variant infections (interaction, p=0.003). XBB.1.5 vaccines protect against severe illness, but protection may be weaker against JN.1 vs XBB-lineage variants. This study highlights the need for COVID-19 vaccines to be routinely updated to align with circulating strains and for individuals to stay up to date with recommended vaccines.

引用

页数：8

共 32 条

[1] COVID data tracker: variant proportions, (2024)
[2] Regan J.J., Moulia D.L., Link-Gelles R., Godfrey M., Mak J., Najdowski M., Et al., Use of updated COVID-19 vaccines 2023–2024 formula for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices — United States, September 2023, Morb Mortal Wkly Rep, 72, (2023)
[3] Yang S., Yu Y., Xu Y., Jian F., Song W., Yisimayi A., Et al., Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure, Lancet Infect Dis, 24, (2024)
[4] Planas D., Staropoli I., Michel V., Lemoine F., Donati F., Prot M., Et al., Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion, Nat Commun, 15, (2024)
[5] Kaku Y., Okumura K., Padilla-Blanco M., Kosugi Y., Uriu K., Hinay A.A., Et al., Virological characteristics of the SARS-CoV-2 JN.1 variant, Lancet Infect Dis, 24, (2024)
[6] Wang Q., Guo Y., Bowen A., Mellis I.A., Valdez R., Gherasim C., Et al., XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1, Cell Host Microbe, 32, (2024)
[7] Chalkias S., McGhee N., Whatley J.L., Essink B., Brosz A., Tomassini J.E., Et al., Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines, J Infect Dis, 230, (2024)
[8] Hansen C.H., Moustsen-Helms I.R., Rasmussen M., Soborg B., Ullum H., Valentiner-Branth P., Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study, Lancet Infect Dis, 24, (2024)
[9] van Werkhoven C.H., Valk A.-W., Smagge B., de Melker H.E., Knol M.J., Hahne S.J., Et al., Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023, Euro Surveill, 29, (2024)
[10] Link-Gelles R., Ciesla A.A., Mak J., Miller J.D., Silk B.J., Lambrou A.S., Et al., Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024, Morb Mortal Wkly Rep, 73, pp. 77-83, (2024)

← 1 2 3 4 →